- SAGE Healthcare Private Limited appointed to serve as a
non-exclusive licensee and distributor for Volition's
Nu.Q® Vet Cancer Screening Test in centralized labs in
Singapore, with launch planned in
Singapore in the first quarter of
2022 followed by expansion in conjunction with SAGE Healthcare into
centralized labs in other key Asian markets.
- Volition's global strategy is to implement similar agreements
with multiple companies to ensure the broadest possible
accessibility to the Nu.Q® Test worldwide.
- Volition continues to make significant progress in ongoing
negotiations with the multi-national veterinary companies referred
to in its prior disclosures, with several term sheets
well-progressed and one or more definitive contracts anticipated in
the first quarter of 2022, to provide global coverage for the Nu.Q®
Test.
AUSTIN, Texas, Dec. 16, 2021 /PRNewswire/ -- VolitionRx Limited
(NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics
company developing simple, easy to use, cost effective blood tests
to help diagnose and monitor a range of cancers and other
life-altering diseases in both humans and animals, has announced
that it has entered into its first contract for the
Nu.Q® Vet Cancer Screening Test, a
supply and licensing agreement with SAGE Healthcare.
"With the global veterinary market being so fragmented, we
determined the best way to ensure our test is accessible worldwide
is to have multiple agreements with both large multi-nationals and
regional players," commented Dr. Tom
Butera, Chief Executive Officer of Volition Veterinary
Diagnostics Development, LLC. "I am delighted to announce this
agreement for centralized labs in Asia, a large and rapidly expanding pet care
market. I expect this will be the first of many agreements,
including with the big multi-nationals, so that we can cover the
whole world through centralized labs and also with point of
care."
https://youtu.be/sZySltlh53w
An interview with Dr.
Tom Butera, Chief Executive Officer
of Volition Veterinary Diagnostics Development LLC.
Dr. Jasmine Kway, Chief Executive
Officer of Singapore Volition commented "With rapid urbanization
and rising disposable income, pets have become an important part of
Asian families. Over half of the Asian population have a companion
animal , with almost a third of households owning a dog. We believe
that the opportunity for the Nu.Q® Vet Cancer Screening
Test is huge. SAGE Healthcare is one of the strongest and most
respected distributors of leading veterinary brands in Singapore. We are pleased to appoint SAGE
Healthcare to offer the Nu.Q® Vet Cancer Screening Test
widely in Singapore and later
avail the Nu.Q® Vet Cancer Screening Test in other
countries in Asia."
"We are delighted to be appointed as a licensee and distributor
of the Nu.Q® Vet Cancer Screening Test in Singapore and other countries in Asia. Adding the Nu.Q® Vet Cancer
Screening Test to the routine wellness check-up for older dogs and
at-risk breeds could help detect cancer early, when treatment is
more effective and affordable. We believe that this is a clear
unmet need in the veterinary space," commented Ms. Irene Kum
General Manager for SAGE Healthcare Private Limited. "We are
excited to launch the test in Singapore in the first quarter of 2022 and
with planned subsequent launches in other Asian markets
thereafter."
To learn more about Volition Veterinary and Nu.Q® Vet
please visit our webpage at
https://volition.com/veterinary
About SAGE
SAGE Healthcare is a leading distributor of premium
veterinary products and services in Asia. Founded by distribution veterans of
clinical and research products, SAGE provides a full array of
distribution services from marketing and sales, supply chain,
education, and registration services. SAGE is headquartered in
Singapore, with businesses in
Malaysia, Thailand, and China.
About Volition
Volition is a multi-national epigenetics company that applies
its Nucleosomics™ platform through its subsidiaries to develop
simple, easy to use, cost effective blood tests to help diagnose
and monitor a range of life-altering diseases including some
cancers and diseases associated with NETosis such as sepsis and
COVID-19. Early diagnosis and monitoring have the potential to not
only prolong the life of patients, but also to improve their
quality of life. The tests are based on the science of
Nucleosomics™, which is the practice of identifying and measuring
nucleosomes in the bloodstream or other bodily fluid - an
indication that disease is present. Volition is primarily focused
on human diagnostics and monitoring but also has a subsidiary
focused on animal diagnostics and monitoring.
Volition's research and development activities are centered in
Belgium, with a small laboratory
in California and additional
offices in Texas, London and Singapore, as the company focuses on bringing
its diagnostic and disease monitoring products to market.
For more information about Volition, visit Volition's website
volition.com or connect with us via:
Twitter: https://twitter.com/volitionrx
LinkedIn: https://www.linkedin.com/company/volitionrx
Facebook: https://www.facebook.com/VolitionRx/
YouTube: https://www.youtube.com/user/VolitionRx
The contents found at Volition's website address, Twitter,
LinkedIn, Facebook, and YouTube are not incorporated by reference
into this document and should not be considered part of this
document. The addresses for Volition's website, Twitter, LinkedIn,
Facebook, and YouTube are included in this document as inactive
textual references only.
Media / Investor Contacts
Louise Batchelor,
Volition
mediarelations@volition.com
+44 (0)7557
774620
|
Scott Powell,
Volition
investorrelations@volition.com
+1 (646) 650
1351
|
Jen Lewis,
Mind&Matter
Jen.Lewis@ashfieldhealth.com
+44 (0)7809
867943
|
Joseph Green,
Edison Advisors
jgreen@edisongroup.com
+1 (646) 653
7030
|
Safe Harbor Statement
Statements in this press release may be "forward-looking
statements" within the meaning of Section 27A of the Securities Act
of 1933, as amended, and Section 21E of the Securities Exchange Act
of 1934, as amended, that concern matters that involve risks and
uncertainties that could cause actual results to differ materially
from those anticipated or projected in the forward-looking
statements. Words such as "expects," "anticipates," "intends,"
"plans," "aims," "targets," "believes," "seeks," "estimates,"
"optimizing," "potential," "goal," "suggests," "could," "would,"
"should," "may," "will" and similar expressions identify
forward-looking statements. These forward-looking statements relate
to, among other topics, the success of negotiations and the timing,
completion and execution of term sheets and/or agreements with
third parties regarding the licensing and distribution of
Volition's products, the effectiveness of Volition's blood-based
diagnostic, prognostic and disease monitoring tests, Volition's
ability to develop and successfully commercialize such test
platforms for early detection of cancer and other diseases as well
as serving as a diagnostic, prognostic or disease monitoring tools
for such diseases, and the timing of product launches and
publications. Volition's actual results may differ materially from
those indicated in these forward-looking statements due to numerous
risks and uncertainties, including, without limitation, results of
studies testing the efficacy of its tests. For instance, if
Volition fails to develop and commercialize diagnostic, prognostic
or disease monitoring products, it may be unable to execute its
plan of operations. Other risks and uncertainties include
Volition's failure to obtain necessary regulatory clearances or
approvals to distribute and market future products; a failure by
the marketplace to accept the products in Volition's development
pipeline or any other diagnostic, prognostic or disease monitoring
products Volition might develop; Volition's failure to secure
adequate intellectual property protection; Volition will face
fierce competition and Volition's intended products may become
obsolete due to the highly competitive nature of the diagnostics
and disease monitoring market and its rapid technological change;
downturns in domestic and foreign economies; and other risks
identified in Volition's most recent Annual Report on Form 10-K and
Quarterly Reports on Form 10-Q, as well as other documents that
Volition files with the Securities and Exchange Commission. These
statements are based on current expectations, estimates and
projections about Volition's business based, in part, on
assumptions made by management. These statements are not guarantees
of future performance and involve risks, uncertainties and
assumptions that are difficult to predict. Forward-looking
statements are made as of the date of this release, and, except as
required by law, Volition does not undertake an obligation to
update its forward-looking statements to reflect future events or
circumstances.
Nucleosomics™ and Nu.Q® and their respective logos are
trademarks and/or service marks of VolitionRx Limited and its
subsidiaries. All other trademarks, service marks and trade names
referred to in this press release are the property of their
respective owners.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/volition-executes-its-first-supply-and-licensing-contract-for-its-nuq-vet-cancer-screening-test-in-asia-301446407.html
SOURCE VolitionRx Limited